Moreover, this study demonstrates that WDR34-targeted gene therapy can effectively delay photoreceptor loss, highlighting a promising treatment strategy for patients with WDR34-related retinal disease. This evidence concerns the gene DYNC2I2 and Abnormal retinal morphology.